Guest post: Excellent care for LGBTQ patients requires cultural humility and specific medical knowledge

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Medicare Part D cliff ahead

Medicare Part D has been providing seniors with access to prescription drug coverage that meets their needs for more than a decade. Today, more than 42 million people are enrolled in Part D and 90...
Read More
Aspen Spotlight Health: Discussing the forefront of innovation

For the second year in a row, PhRMA is proud to participate in Aspen’s Spotlight Health Conference. As the opening session of Aspen Ideas Festival, Spotlight Health welcomes over 1,500 experts and...
Read More
Patients with a deductible have seen their out-of-pocket costs for brand medicines increase 50 percent since 2014

Spending on medicines is growing at the slowest rate in years, but according to a new IQVIA Institute for Human Data Science article, at the pharmacy, commercially insured patients with a deductible...
Read More
Celebrating U.S. innovation as USPTO issues the 10 millionth patent

The U.S. patent system has supported innovation and discovery dating back to the founding of our nation and the signing of the U.S. Constitution, encouraging Americans to continue to search for the...
Read More
Long-awaited FDA guidance addresses one key obstacle to value-based contracting

As part of the broader shift away from paying for volume to paying for value in health care, payors are increasingly pursuing value-based or results-based contracts with biopharmaceutical companies....
Read More
ICYMI - Analysis finds higher outpatient drug spending at 340B hospitals

Did you know 340B hospitals prescribe more medicines or more expensive medicines? A recent analysis by Milliman, commissioned by PhRMA, found hospitals participating in the 340B drug pricing program...
Read More
Part D cliff looms for seniors, as program stability could be in jeopardy

For more than a decade, Medicare Part D has successfully provided seniors comprehensive prescription drug coverage that meets their needs, while its market-based structure has kept overall program...
Read More
Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill

This week, the new era of medicine was brought to Capitol Hill in Washington, DC when 55 biopharmaceutical researchers from 20 PhRMA member companies held 79 meetings with members of Congress and...
Read More
Diversity of thought fuels next generation of breakthroughs

This month, PhRMA is proud to join with our member companies to celebrate Lesbian, Gay, Bisexual and Transgender (LGBT) PRIDE Month.
Read More
New analysis shows that more medicines worldwide are available to U.S. patients

In the past year, we have seen revolutionary new treatments become available to patients in the United States for cancer and other debilitating diseases. A new analysis puts in perspective the...
Read More
New analysis shows that HTA organizations may frequently restrict access to cancer treatments

In health care, who should decide value? In many industrialized countries with single-payer health systems, the answer is “the government.” A new analysis by Avalere illustrates the negative impact...
Read More